Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 15/20 | 0.57 |
| ▸ | ITGA4 | P13612 | 15/20 | 0.57 |
| ▸ | PTGER3 | P43115 | 5/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8345907 | 0.86 | ITGB1 (0.77) | ITGB1ITGA4 | |
| SCHEMBL5070973 | 0.79 | ITGB1 (0.44) | ITGB1ITGA4KDM4EALDH1A1MAPT | |
| SCHEMBL8345904 | 0.77 | ITGB1 (0.62) | ITGB1ITGA4KDM4EMEN1MAPT | |
| SCHEMBL5068351 | 0.77 | ITGB1 (0.82) | ITGB1ITGA4KDM4EMAPTRAB9A | |
| SCHEMBL8345937 | 0.75 | ITGB1 (0.54) | ITGB1ITGA4KDM4EMEN1MAPT | |
| SCHEMBL5069282 | 0.73 | ITGB1 (0.77) | ITGB1ITGA4 | |
| SCHEMBL5066815 | 0.73 | ITGB1 (0.77) | ITGB1ITGA4 | |
| SCHEMBL5068391 | 0.73 | ITGB1 (0.77) | ITGB1ITGA4 | |
| SCHEMBL5068926 | 0.73 | ITGB1 (1.00) | ITGB1ITGA4 | |
| SCHEMBL5066874 | 0.73 | ITGB1 (1.00) | ITGB1ITGA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7410984-B2 | Compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-08-12 | — | — | US | disclosed |
| US-20050288337-A1 | Novel compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288337-A1 | Novel compounds | ITGB4, ITGA4, ITGB5 | ITGB1 5/4885ITGA4 2/4885PTGER3 1141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.